Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi

Francesco Zaja, Flavia Salvi, Maura Rossi, Elena Sabattini, Andrea Evangelista, Giovannino Ciccone, Emanuele Angelucci, Gianluca Gaidano, Manuela Zanni, Marco Ladetto, Annalisa Chiappella, Umberto Vitolo, Pier Luigi Zinzani, Catello Califano, Alessandra Tucci, Caterina Patti, Stefano A Pileri, Valentina Lenti, Pier Paolo Piccaluga, Federica CavalloStefano Volpetti, Giulia Perali, Sarit Assouline, Koren Kathleen Mann, Ryan Morin, Miguel Alcaide, Kevin Bushell, Renato Fanin, Alessandro Levis

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated panobinostat 40 mg three times weekly in 35 adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Overall response rate and complete response were 17.1% and 11.4%, respectively. Median progression-free survival (PFS) and overall survival were 2.4 and 7.6 months, respectively. Calculated 12, 24 and 36 months PFS were 26%, 11% and 11%, respectively. Four patients who achieved a sustained CR, continued receiving panobinostat for an overall period of 44, 48, 50, 62 months. Thrombocytopenia grade 3 (5 patients) and 4 (24 patients) represented the main toxic effect, causing dose reduction or treatment suspension in 19 patients. Genomic analysis was unable to identify any relationship between mutations and response; TP53 mutation appeared not to impact the clinical outcome. Overall, panobinostat has a modest activity in R/R DLBCL patients, however it can induce very long lasting responses in some cases. Thrombocytopenia frequently limits the use of this agent.

Original languageEnglish
Pages (from-to)2904-2910
Number of pages7
JournalLeukemia and Lymphoma
Volume59
Issue number12
DOIs
Publication statusPublished - Dec 2018

Fingerprint Dive into the research topics of 'Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi'. Together they form a unique fingerprint.

Cite this